HK2 and familial pancreatic carcinoma: Benitrobenrazide, an innovative selective HK2 inhibitor, demonstrates the capability to target the binding site and preclude glucose association with HK2, thus efficaciously inhibiting pancreatic cancer growth by disrupting glycolytic pathways.146